📬 Lung/Head and Neck/Thymoma Intelligence Digest — Week 2026-W42
FURVENT misses its PFS endpoint in EGFR exon 20 insertion NSCLC while S1914 publishes in the Lancet confirming SBRT alone, LAURA's post-progression data land in CCR, and DCLung26 debates resectability, biomarker testing and SCLC sequencing.
⚡ TL;DR
📄 Publications
- Type II ROS1 Inhibition Overcomes Type I Inhibitor Resistance in ROS1 Fusion-Positive Lung Cancers: A Phase II Trial of Cabozantinib. — Single-centre phase 2 enrolled 7 ROS1 TKI pre-treated patients with ROS1 fusion-positive NSCLC previously treated with crizotinib, entrectinib, repotrectinib and zidesamtinib
- FIND: a phase-II study to evaluate the efficacy and safety of erdafitinib in FGFR-altered NSCLC. — FGFR alterations occur in approximately 2% of NSCLC, predominantly in squamous histology
🐦 Twitter / 🦋 Bluesky
- First-line MET TKI versus immunotherapy in METex14 NSCLC: PD-L1 level and metastatic site split the decision — A published study of first-line MET TKIs versus immunotherapy ± chemotherapy in METex14 NSCLC found ICI±chemo benefit in tumors with very high PD-L1 while MET TKIs extended survival in patients with lower PD-L1 or brain/bone involvement
- FURVENT misses its PFS primary endpoint with 1L firmonertinib in EGFR exon 20 insertion NSCLC, and the control arm is blamed — Phase III FURVENT of first-line firmonertinib monotherapy versus pemetrexed-based chemotherapy did not meet its primary endpoint of PFS in EGFR exon 20 insertion mutant NSCLC
- The second Florence International Consensus extends radiation-plus-systemic-therapy recommendations to head and neck cancer — The 2nd Florence International Consensus on combining radiation therapy with new systemic therapies extended its focus beyond breast cancer to include head & neck cancer, kidney cancer and prostate cancer, with statements endorsed by ESTRO
- Update: the ADAURA 8-year landmark discussion shifts to patient preference and the cost of adjuvant osimertinib — A survey exploring patient preferences for adjuvant osimertinib after resection of EGFR NSCLC found DFS was sufficient for most, but 33% would not pay even with an OS benefit
- Only about half of stage III NSCLC patients given neoadjuvant chemoimmunotherapy reach the operating room, and the specialty discord is now open — Moghanaki states the percentage of stage III NSCLC patients who actually reach the operating room after neoadjuvant chemoimmunotherapy is not 80% as in phase III RCTs but closer to 50%
Full details below ↓
📄 What's Being Published
Drug-specific resistance mechanisms to RET inhibitors in RET fusion-positive NSCLC. — Liu Ximeng et al., Clin Cancer Res
RET fusions occur in approximately 1-2% of NSCLC, and acquired resistance to selpercatinib and pralsetinib inevitably develops. Secondary RET mutations conferred resistance in a drug-specific manner: V804E/M to selpercatinib, L730I/V and A883V to pralsetinib (A883V newly identified), and G810C/D/S, Y806N and E732K to both. In a retrospective cohort, one patient who acquired G810X mutations at progression on selpercatinib achieved a durable response to pralsetinib.
Clinical bottom line: At progression on a selective RET inhibitor, re-biopsy and sequencing can identify a drug-specific secondary mutation. That finding makes switching to the other approved RET inhibitor a rational choice rather than a coin flip.
A randomized trial to evaluate the effect of epigallocatechin gallate (EGCG) on EBV reactivation in patients with nasopharyngeal carcinoma in remission -the TCOG T2312 study. — Tsai Hui-Jen et al., Eur J Cancer
Of 353 patients with nasopharyngeal carcinoma in remission, 327 were evaluable: 161 were randomized to EGCG and 166 to placebo. EBV DNA reactivation and recurrence rates did not differ significantly between groups, and EGCG toxicity was minimal. Positive plasma EBV DNA was significantly associated with a high recurrence rate and short RFS and OS.
Clinical bottom line: Green tea extract should not be offered to prevent EBV reactivation in nasopharyngeal carcinoma in remission. The trial does support continuing serial plasma EBV DNA as a surveillance marker.
Type II ROS1 Inhibition Overcomes Type I Inhibitor Resistance in ROS1 Fusion-Positive Lung Cancers: A Phase II Trial of Cabozantinib. — Rubio-Perez Jaime et al., Clin Cancer Res
The trial enrolled 7 ROS1 TKI-pretreated patients previously treated with crizotinib, entrectinib, repotrectinib and zidesamtinib. ORR was 43% (95% CI, 10-81.5%), with a best response of -92% in a ROS1 D2033N mutant cancer and a -49% PR in a ROS1 G2032R/L2086F mutant cancer. Median PFS was 4.5 months (95% CI, 4-NE), median DoR 8.0 months and median OS 11 months (95% CI, 6-NE). Grade 3 treatment-related adverse events occurred in 57%, mostly palmar-plantar erythrodysesthesia and transaminitis, and all patients required a dose reduction.
Clinical bottom line: Cabozantinib is a defensible off-label option for the small group of ROS1 fusion-positive patients with on-target resistance mutations after type I TKIs. The trade-offs are that every patient needed a dose reduction and PFS is short.
FIND: a phase-II study to evaluate the efficacy and safety of erdafitinib in FGFR-altered NSCLC. — Nogova Lucia et al., Clin Cancer Res
FGFR alterations occur in approximately 2% of NSCLC, predominantly in squamous histology. Of 44.537 patients screened in nNGM, 22 were treated with erdafitinib: 7 in cohort 1, 8 in cohort 2 and 7 in cohort 3. In the FGFR fusion cohort, two of 7 patients achieved partial response (one unconfirmed), while the best response in the mutation cohort was stable disease. The most common any-grade adverse events were hyperphosphatemia in 45.5% and diarrhea and dry mouth, each in 31.8%.
Clinical bottom line: In NSCLC, erdafitinib showed a signal only in FGFR fusions, not FGFR mutations. Given the yield from screening 44,537 patients, FGFR inhibition remains investigational outside trials.
First-line toripalimab in combination with platinum-doublet chemotherapy for advanced B3 thymoma and thymic carcinoma: an open-label prospective phase Ⅱ trial. — Zhu K et al., ESMO Open
The trial enrolled 24 patients, who received paclitaxel, carboplatin and toripalimab for up to six cycles followed by toripalimab maintenance. Median PFS was 19.3 months (95% CI 12.8-25.8). ORR was 37.5% (95% CI 18.8%-59.4%) and disease control rate 100% (95% CI 85.8%-100%). Grade 3-4 TRAEs occurred in 12 (50.0%) patients and irAEs in 11 (45.8%), with grade ≥3 irAEs in 1 (4.2%).
Clinical bottom line: Adding toripalimab to carboplatin-paclitaxel is a reasonable first-line option for advanced B3 thymoma and thymic carcinoma in centres comfortable monitoring immune toxicity. Nearly half of patients had an irAE, but only one was severe.
🗂 Every paper considered this week, including the ones that didn’t make it →
🗣️ What People Were Discussing This Week
How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).
First-line MET TKI versus immunotherapy in METex14 NSCLC: PD-L1 level and metastatic site split the decision
A multi-institution study in CCR (Pecci, Li et al.) compared first-line MET TKIs with immunotherapy ± chemotherapy in METex14 NSCLC. It found no overall PFS difference by starting therapy, ICI±chemo benefit in tumors with very high PD-L1, and longer survival with capmatinib or tepotinib in patients with lower PD-L1 or brain/bone involvement. Real-world Italian and IFCT-2104 CAPMATU cohorts reported MET inhibitor response rates, with higher responses in first line than later lines. At DCLung26, the open question was whether starting immunotherapy rather than a MET TKI is defensible outside a trial in PD-L1-high disease without CNS involvement, and how resistance patterns should guide the next line.
Key numbers: MET inhibitor RR 46% 1L vs 33% later lines · Capmatinib mPFS 4.8m, mOS 10.4m, RR 55.3% · Capmatinib 1L mPFS 7.7m · Intracranial RR 41%
Discussed by: @BRicciutiMD, @StephenVLiu, @StephenVLiu, @StephenVLiu, @JeongminSeoMD, @LauraAlderMD, @LeXiuning
Sources cited: First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patient… (Clinical Cancer Research, 2025) · ESMO Open · Lung Cancer
FURVENT misses its PFS primary endpoint with 1L firmonertinib in EGFR exon 20 insertion NSCLC, and the control arm is blamed
Phase III FURVENT of first-line firmonertinib versus platinum/pemetrexed did not significantly improve BICR-assessed PFS in EGFR exon 20 insertion NSCLC. Response rate favored firmonertinib, and immature OS trends in its favor, but the data so far come from a press release. Gandara argued the control arm performed much better than expected for this genomic subset. Patil read the result, together with PAPILLON and REZILIENT3, as evidence that upfront platinum chemotherapy belongs in the exon 20 strategy, which leaves open whether TKI monotherapy remains viable in this subset; firmonertinib is already approved in China for this indication.
Key numbers: 240 mg mPFS 11.0 vs 9.5 mo, HR 0.75 (95% CI 0.55–1.02), p=0.0654 · ORR 60% vs 33% · 160 mg mPFS 8.4 vs 9.5 months, HR 0.91
Discussed by: @StephenVLiu, @M_Torasawa, @M_Torasawa, @drgandara, @TejasPatilMD, @tnewsomdavis, @phsiao4, @EgfrUk, @Exon20Group, @lungoncdoc
Sources cited: Cancer Network
The second Florence International Consensus extends radiation-plus-systemic-therapy recommendations to head and neck cancer
The 2nd Florence International Consensus moved beyond breast cancer to cover head and neck, kidney and prostate cancer. Blanchard credited IMRT and concurrent cisplatin as the defining innovations in head and neck care, noting that proton and adaptive radiotherapy still lack consistent trials showing clear benefit. The head and neck message was to de-intensify good-prognosis disease and, because dose escalation has largely failed in poor-prognosis disease, to seek gains by combining systemic therapy with better local treatment. Sessions addressed induction intensification in nasopharyngeal carcinoma and cure of oligometastatic HNSCC, leaving open whether the statements actually guide when to pause versus combine therapy.
Discussed by: @OncoAlert, @PBlanchardMD, @MarcBa12, @MarcBa12, @weoncologists
Update: the ADAURA 8-year landmark discussion shifts to patient preference and the cost of adjuvant osimertinib
The exploratory 8-year ADAURA landmark analysis of 3 years of adjuvant osimertinib in resected stage IB-IIIA EGFR-mutant NSCLC showed a sustained OS benefit, stronger in Ex19del than L858R. A patient-preference survey found DFS sufficient for most, but cost was a major barrier: a third would not pay even with an OS benefit. Open questions include optimum duration, MRD use, de-escalation, and whether chemotherapy can be omitted, which the OCEANiC trial is testing. The debate centres on how to build financial toxicity into the adjuvant conversation.
Key numbers: 8-y OS 74% vs 58%, HR 0.53 · Stage IB-IIIA 79% vs 64%, HR 0.52 · mOS 92 mo vs 68.5 mo, HR 0.53 · Ex19del HR 0.45 vs L858R HR 0.72 · HR 0.48 at 5 years vs 0.52 at 8 years
Discussed by: @StephenVLiu, @Latinamd, @drsabita, @TommyJohn00, @DrewMoghanaki
Only about half of stage III NSCLC patients given neoadjuvant chemoimmunotherapy reach the operating room, and the specialty discord is now open
Moghanaki stated that the share of stage III NSCLC patients reaching surgery after neoadjuvant chemoimmunotherapy is not 80%, as in phase III RCTs that required operability confirmation, but closer to 50%. He called specialist discord unprecedented. Siva amplified the point that some derailed patients never receive any local therapy. West agreed enthusiasm is prone to irrational exuberance, driven partly by patients' pull to "get it out", but argued the same selection concern applies to SBRT. The open question is who should decide operability, and whether radiation oncology sign-off should precede the first cycle.
Discussed by: @DrewMoghanaki, @JackWestMD, @_ShankarSiva, @DrewMoghanaki
Sources cited: Lung Cancer
Biomarker testing at DCLung26: RNA fusion panels, dual tissue-plasma strategy and the limits of a negative liquid biopsy
Aggarwal argued that comprehensive genomic testing must include RNA fusion panels and that a negative liquid biopsy may reflect insufficient ctDNA rather than the absence of a driver. A WCLC study found one more MET exon 14 case by adding RNA analysis to a blood-based DNA test, prompting clinicians to ask whether their blood test covers ctRNA. Others stressed that assays differ in coverage and results, and recommended testing early, thinking beyond DNA, and using both tissue and plasma. The debate is whether paired tissue plus plasma NGS with RNA up front is standard or unaffordable redundancy outside academic centres.
Discussed by: @LauraAlderMD, @metcrusaders, @Joshua_Reuss, @drshieldsmd, @Latinamd, @GlopesMd
JCOG 0802 update: lobectomy is associated with inferior overall survival in stage I NSCLC even with high-risk pathological findings
The JCOG 0802 update again associates lobectomy with inferior OS in surgically managed stage I NSCLC, now among patients with high-risk pathology (LVI, VSI, pleural invasion or lymph node metastasis), even though lobectomy improves RFS. At DCLung26, clinicians argued that stage alone does not tell the whole story and that tumor biology matters, while case discussions highlighted resectability, biomarker testing and centre expertise. The question raised is whether segmentectomy should become the default, with lobectomy the exception.
Discussed by: @DrewMoghanaki, @lungoncdoc, @Latinamd
Sources cited: JTO
SKYSCRAPER-02C reports a China-only PFS and OS signal for tiragolumab in extensive-stage SCLC after the global trial was negative
In the phase 3 China study of atezolizumab plus carboplatin/etoposide with or without tiragolumab, patients without brain metastases showed improved PFS and OS with tiragolumab, although the global SKYSCRAPER-02 was negative. Exploratory analyses suggested greater benefit in immune-inflamed subtypes and tumors with stronger T-effector and macrophage signatures, consistent with the Lancet SCLC framework of molecular states carrying immune-directed vulnerabilities. The debate is whether a positive regional result justifies a biomarker-selected TIGIT trial.
Key numbers: mPFS 5.4 → 5.6 months, HR 0.65 · OS 13.5 → 18.7 months, HR 0.89
Discussed by: @ChandrakanthMv, @NaglaAKarimMD
Sources cited: ovid.com
The NCCN 6-week postoperative radiotherapy metric in head and neck cancer comes under methodological attack
Critics called the NCCN rule to start postoperative radiotherapy within 6 weeks of surgery a continuous variable chopped into a binary cutoff with no biology behind it. Others argued reverse causality: wound healing problems, comorbidities and social determinants delay radiotherapy, so poor prognosis causes the delay. Cramer noted that faster PORT has not been shown to improve outcomes, that the CHUM study (NCT07180901) should help answer this, and that the 6-week threshold was simply an easier first metric to agree on. A related analysis linked earlier radiation oncology evaluation to more timely PORT, leaving open whether the metric should stay without survival evidence.
Discussed by: @jryckman3, @jryckman3, @Jdcramer, @jryckman3
Sources cited: Mechanisms Underlying an Enhanced Navigation-Based Intervention to Improve Timely Adjuvan… (JAMA Otolaryngology–Head & Neck Surgery, 2026)
LAURA's post-progression analysis publishes in CCR: osimertinib after chemoradiation delays subsequent therapy by over three years
The LAURA update in CCR shows that post-progression endpoints favor osimertinib after definitive chemoradiation for EGFR-mutant NSCLC, with time to first subsequent therapy sharply prolonged. OS remains immature, and most placebo patients who discontinued went on to receive osimertinib. The debate is whether the subsequent-therapy benefit is enough to commit stage III patients to indefinite consolidation before OS matures.
Key numbers: TFST 43.8 vs 9.5 months, HR 0.13 · PFS2 HR 0.62 (P=0.088) · TSST HR 0.51 · Interim OS HR 0.67 (0.40-1.14, 31% maturity) · Subsequent osimertinib 22% vs 76%
Discussed by: @StephenVLiu, @M_Torasawa, @phsiao4
Sources cited: Osimertinib after Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSC… (Clinical Cancer Research, 2026)
Cabozantinib as a type II ROS1 inhibitor produces deep responses in multi-drug-resistant ROS1 fusion-positive NSCLC
A phase II CCR report of cabozantinib, a type II ROS1/MET inhibitor, in ROS1 NSCLC showed a response rate of 43%, including a deep response in a patient with the ROS1 D2033N mutation. This supports a role for cabozantinib after on-target resistance to the type I inhibitors that make up all approved ROS1 therapies. Four agents are approved first line, zidesamtinib is approved second line, and the FDA cleared a taletrectinib sNDA for TKI-naive patients four months ahead of its PDUFA date. Clinicians questioned where an off-label type II inhibitor fits in that sequence.
Discussed by: @StephenVLiu, @StephenVLiu, @Joshua_Reuss, @drshieldsmd
Sources cited: Type II ROS1 Inhibition Overcomes Type I Inhibitor Resistance in ROS1 Fusion-Positive Lun… (Clin Cancer Res) · OncLive
ConCERT publishes: weekly cisplatin is non-inferior to 3-weekly in definitive chemoradiation for locally advanced head and neck cancer
In the phase 3 ConCERT trial in JNCI, weekly cisplatin 40 mg/m² was non-inferior to 3-weekly 100 mg/m² in definitive chemoradiation for LA-HNSCC, with 2-year locoregional control of 61.3% vs 51.1%, less toxicity and fewer admissions. At Florence, concurrent cisplatin was named one of the two innovations that changed head and neck care. The question is whether the weekly schedule should now become the default concurrent regimen.
Discussed by: @Jdcramer, @OncoAlert
Sources cited: Concurrent chemotherapy and external radiation therapy (ConCERT): phase 3 noninferiority… (JNCI: Journal of the National Cancer Institute, 2026)
🔥 Top Ranked Tweets
Sara Coca Membribes @scocmem
RT @OncoAlert: Is topotecan finished in relapsed SCLC? 🫁
Two phase 3 trials of B7-H3 ADCs both beat it:
🔹 Tam-Peli (NEJM): OS 13.3 vs 9.4 mo, HR 0.46. ORR 59% vs 10%.
https://t.co/pO4dceeRCb
🔹 Ris-Rez (ARTEMIS-008, #WCLC26): OS 18.5 vs 10.3 mo, HR 0.46. ORR 58% vs 13%.
Both also had fewer grade ≥3 AEs than topotecan.
https://t.co/uQ8s7VcwXB
🎥 Dr. @UOzkerim& Dr. Aslı Geçgel from Istanbul 🇹🇷 break down what this means for practice.
#LCSM #SCLC #LungCancer
@peters_solange, @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @jillfeldman4, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @UOzkerim, @FernandoOnco, @DrMirallas, @VanitaNoronha, @NarjustFlorezMD, @MartinReck2, @realbowtiedoc, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @p_ciracimd, @AmandaNizamMD, @scocmem, @DrVilmaPBarcia, @DraMartinezLago, @nataliagandur, @GIMedOnc, @DaisukeKotani
🔖 4 ❤️ 22 🔁 12 👁 2,411
OncoAlert @OncoAlert
Is topotecan finished in relapsed SCLC? 🫁
Two phase 3 trials of B7-H3 ADCs both beat it:
🔹 Tam-Peli (NEJM): OS 13.3 vs 9.4 mo, HR 0.46. ORR 59% vs 10%.
https://t.co/pO4dceeRCb
🔹 Ris-Rez (ARTEMIS-008, #WCLC26): OS 18.5 vs 10.3 mo, HR 0.46. ORR 58% vs 13%.
Both also had fewer grade ≥3 AEs than topotecan.
https://t.co/uQ8s7VcwXB
🎥 Dr. @UOzkerim& Dr. Aslı Geçgel from Istanbul 🇹🇷 break down what this means for practice.
#LCSM #SCLC #LungCancer
@peters_solange, @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @jillfeldman4, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @UOzkerim, @FernandoOnco, @DrMirallas, @VanitaNoronha, @NarjustFlorezMD, @MartinReck2, @realbowtiedoc, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @p_ciracimd, @AmandaNizamMD, @scocmem, @DrVilmaPBarcia, @DraMartinezLago, @nataliagandur, @GIMedOnc, @DaisukeKotani
🔖 4 ❤️ 22 🔁 12 👁 2,411
Gil Morgan, MD @weoncologists
RT @OncoAlert: Is topotecan finished in relapsed SCLC? 🫁
Two phase 3 trials of B7-H3 ADCs both beat it:
🔹 Tam-Peli (NEJM): OS 13.3 vs 9.4 mo, HR 0.46. ORR 59% vs 10%.
https://t.co/pO4dceeRCb
🔹 Ris-Rez (ARTEMIS-008, #WCLC26): OS 18.5 vs 10.3 mo, HR 0.46. ORR 58% vs 13%.
Both also had fewer grade ≥3 AEs than topotecan.
https://t.co/uQ8s7VcwXB
🎥 Dr. @UOzkerim& Dr. Aslı Geçgel from Istanbul 🇹🇷 break down what this means for practice.
#LCSM #SCLC #LungCancer
@peters_solange, @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @jillfeldman4, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @UOzkerim, @FernandoOnco, @DrMirallas, @VanitaNoronha, @NarjustFlorezMD, @MartinReck2, @realbowtiedoc, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @p_ciracimd, @AmandaNizamMD, @scocmem, @DrVilmaPBarcia, @DraMartinezLago, @nataliagandur, @GIMedOnc, @DaisukeKotani
🔖 4 ❤️ 22 🔁 12 👁 2,412
OncoAlert @OncoAlert
🧬 Could immune biology finally tell us which patients with extensive-stage SCLC are most likely to benefit from TIGIT-based therapy?
https://t.co/NmzW3ITuAk
SKYSCRAPER-02C🫁 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage #SCLC in China🇨🇳
SKYSCRAPER-02C 🏢 evaluated tiragolumab plus atezolizumab and chemotherapy versus atezolizumab plus chemotherapy in untreated extensive-stage SCLC in China.
➡️ In patients without brain metastases, tiragolumab improved median PFS from 5.4 to 5.6 months (HR 0.65) and OS from 13.5 to 18.7 months (HR 0.89), although global SKYSCRAPER-02 was negative.
➡️ Exploratory biomarker analyses suggested greater benefit in immune-inflamed molecular subtypes and tumors with stronger T-effector and macrophage signatures.
#LungCancer
@peterssolange @christinelovly @GlopesMd @DrSanjayPopat @StephenVLiu @HenningWillers @HHorinouchi @BRicciutiMD @PercyLeeMD @jillfeldman4 @bensolomon1 @Latinamd @DrJNaidoo @barlesi @UOzkerim @FernandoOnco @DrMirallas @VanitaNoronha @NarjustFlorezMD @MartinReck2 @realbowtiedoc @ElisaAgostinett @tobeelizabeth @MarioBalsaMD @p_ciracimd @AmandaNizamMD @scocmem @DrVilmaPBarcia @DraMartinezLago @nataliagandur @GIMedOnc @DaisukeKotani
🔖 1 ❤️ 15 🔁 4 👁 1,381
Gil Morgan, MD @weoncologists
RT @OncoAlert: 🧬 Could immune biology finally tell us which patients with extensive-stage SCLC are most likely to benefit from TIGIT-based therapy?
https://t.co/NmzW3ITuAk
SKYSCRAPER-02C🫁 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage #SCLC in China🇨🇳
SKYSCRAPER-02C 🏢 evaluated tiragolumab plus atezolizumab and chemotherapy versus atezolizumab plus chemotherapy in untreated extensive-stage SCLC in China.
➡️ In patients without brain metastases, tiragolumab improved median PFS from 5.4 to 5.6 months (HR 0.65) and OS from 13.5 to 18.7 months (HR 0.89), although global SKYSCRAPER-02 was negative.
➡️ Exploratory biomarker analyses suggested greater benefit in immune-inflamed molecular subtypes and tumors with stronger T-effector and macrophage signatures.
#LungCancer
@peterssolange @christinelovly @GlopesMd @DrSanjayPopat @StephenVLiu @HenningWillers @HHorinouchi @BRicciutiMD @PercyLeeMD @jillfeldman4 @bensolomon1 @Latinamd @DrJNaidoo @barlesi @UOzkerim @FernandoOnco @DrMirallas @VanitaNoronha @NarjustFlorezMD @MartinReck2 @realbowtiedoc @ElisaAgostinett @tobeelizabeth @MarioBalsaMD @p_ciracimd @AmandaNizamMD @scocmem @DrVilmaPBarcia @DraMartinezLago @nataliagandur @GIMedOnc @DaisukeKotani
🔖 1 ❤️ 15 🔁 4 👁 1,382
OncoAlert @OncoAlert
RT @OncoAlert: Does adding immunotherapy to SBRT ☢️ actually improve outcomes in early-stage, medically inoperable NSCLC🫁 —or simply add toxicity?
https://t.co/4JQVf24q3j
Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914)
A phase 3 multicentre trial evaluated whether adding atezolizumab to stereotactic body radiation therapy (SBRT) improves📈 outcomes in medically inoperable early-stage #NSCLC #LungCancer.
➡️ Among 402 eligible patients, atezolizumab plus SBRT did not improve overall survival compared with SBRT alone, with identical estimated 2-year survival of 82%. ➡️Combination therapy also increased grade ≥3 adverse events (12% vs 3%) and included two grade 5 respiratory events, supporting SBRT alone as standard treatment.
@AparGanti, @KashaniRojano, @joyfelicianomd, @NLindqwister, @DrMaraboyina, @KHigginsMD, @JhanelleGray, @karenkellymd
Pinging our faculty
@peters_solange, @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @jillfeldman4, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @UOzkerim, @FernandoOnco, @DrMirallas, @VanitaNoronha, @NarjustFlorezMD, @MartinReck2, @realbowtiedoc, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @p_ciracimd, @AmandaNizamMD, @scocmem, @DrVilmaPBarcia, @DraMartinezLago, @nataliagandur, @GIMedOnc, @DaisukeKotani
🔖 2 ❤️ 29 🔁 14 👁 4,638
Oncology Brothers @OncBrothers
RT @OncoAlert: Does adding immunotherapy to SBRT ☢️ actually improve outcomes in early-stage, medically inoperable NSCLC🫁 —or simply add toxicity?
https://t.co/4JQVf24q3j
Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914)
A phase 3 multicentre trial evaluated whether adding atezolizumab to stereotactic body radiation therapy (SBRT) improves📈 outcomes in medically inoperable early-stage #NSCLC #LungCancer.
➡️ Among 402 eligible patients, atezolizumab plus SBRT did not improve overall survival compared with SBRT alone, with identical estimated 2-year survival of 82%. ➡️Combination therapy also increased grade ≥3 adverse events (12% vs 3%) and included two grade 5 respiratory events, supporting SBRT alone as standard treatment.
@AparGanti, @KashaniRojano, @joyfelicianomd, @NLindqwister, @DrMaraboyina, @KHigginsMD, @JhanelleGray, @karenkellymd
Pinging our faculty
@peters_solange, @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @jillfeldman4, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @UOzkerim, @FernandoOnco, @DrMirallas, @VanitaNoronha, @NarjustFlorezMD, @MartinReck2, @realbowtiedoc, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @p_ciracimd, @AmandaNizamMD, @scocmem, @DrVilmaPBarcia, @DraMartinezLago, @nataliagandur, @GIMedOnc, @DaisukeKotani
🔖 2 ❤️ 29 🔁 14 👁 4,638
OncoAlert @OncoAlert
Does adding immunotherapy to SBRT ☢️ actually improve outcomes in early-stage, medically inoperable NSCLC🫁 —or simply add toxicity?
https://t.co/4JQVf24q3j
Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914)
A phase 3 multicentre trial evaluated whether adding atezolizumab to stereotactic body radiation therapy (SBRT) improves📈 outcomes in medically inoperable early-stage #NSCLC #LungCancer.
➡️ Among 402 eligible patients, atezolizumab plus SBRT did not improve overall survival compared with SBRT alone, with identical estimated 2-year survival of 82%. ➡️Combination therapy also increased grade ≥3 adverse events (12% vs 3%) and included two grade 5 respiratory events, supporting SBRT alone as standard treatment.
@AparGanti, @KashaniRojano, @joyfelicianomd, @NLindqwister, @DrMaraboyina, @KHigginsMD, @JhanelleGray, @karenkellymd
Pinging our faculty
@peters_solange, @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @jillfeldman4, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @UOzkerim, @FernandoOnco, @DrMirallas, @VanitaNoronha, @NarjustFlorezMD, @MartinReck2, @realbowtiedoc, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @p_ciracimd, @AmandaNizamMD, @scocmem, @DrVilmaPBarcia, @DraMartinezLago, @nataliagandur, @GIMedOnc, @DaisukeKotani
🔖 2 ❤️ 29 🔁 14 👁 4,638
gilberto lopes @GlopesMd
RT @OncoAlert: Does adding immunotherapy to SBRT ☢️ actually improve outcomes in early-stage, medically inoperable NSCLC🫁 —or simply add toxicity?
https://t.co/4JQVf24q3j
Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914)
A phase 3 multicentre trial evaluated whether adding atezolizumab to stereotactic body radiation therapy (SBRT) improves📈 outcomes in medically inoperable early-stage #NSCLC #LungCancer.
➡️ Among 402 eligible patients, atezolizumab plus SBRT did not improve overall survival compared with SBRT alone, with identical estimated 2-year survival of 82%. ➡️Combination therapy also increased grade ≥3 adverse events (12% vs 3%) and included two grade 5 respiratory events, supporting SBRT alone as standard treatment.
@AparGanti, @KashaniRojano, @joyfelicianomd, @NLindqwister, @DrMaraboyina, @KHigginsMD, @JhanelleGray, @karenkellymd
Pinging our faculty
@peters_solange, @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @jillfeldman4, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @UOzkerim, @FernandoOnco, @DrMirallas, @VanitaNoronha, @NarjustFlorezMD, @MartinReck2, @realbowtiedoc, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @p_ciracimd, @AmandaNizamMD, @scocmem, @DrVilmaPBarcia, @DraMartinezLago, @nataliagandur, @GIMedOnc, @DaisukeKotani
🔖 2 ❤️ 29 🔁 14 👁 4,640
Gil Morgan, MD @weoncologists
RT @OncoAlert: Does adding immunotherapy to SBRT ☢️ actually improve outcomes in early-stage, medically inoperable NSCLC🫁 —or simply add toxicity?
https://t.co/4JQVf24q3j
Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914)
A phase 3 multicentre trial evaluated whether adding atezolizumab to stereotactic body radiation therapy (SBRT) improves📈 outcomes in medically inoperable early-stage #NSCLC #LungCancer.
➡️ Among 402 eligible patients, atezolizumab plus SBRT did not improve overall survival compared with SBRT alone, with identical estimated 2-year survival of 82%. ➡️Combination therapy also increased grade ≥3 adverse events (12% vs 3%) and included two grade 5 respiratory events, supporting SBRT alone as standard treatment.
@AparGanti, @KashaniRojano, @joyfelicianomd, @NLindqwister, @DrMaraboyina, @KHigginsMD, @JhanelleGray, @karenkellymd
Pinging our faculty
@peters_solange, @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @jillfeldman4, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @UOzkerim, @FernandoOnco, @DrMirallas, @VanitaNoronha, @NarjustFlorezMD, @MartinReck2, @realbowtiedoc, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @p_ciracimd, @AmandaNizamMD, @scocmem, @DrVilmaPBarcia, @DraMartinezLago, @nataliagandur, @GIMedOnc, @DaisukeKotani
🔖 2 ❤️ 29 🔁 14 👁 4,640
CancerNetwork® @CancerNetwrk
SRS did not improve time to neurocognitive failure compared with hippocampal-avoidant whole brain radiotherapy plus memantine but was associated with longer OS in patients with brain mets from SCLC.
https://t.co/E0hQ6g9c9Y
#lcsm #SCLC #btsm #oncology #cancer
🔖 1 ❤️ 0 🔁 0 👁 610
Tom Newsom-Davis @tnewsomdavis
New developments in EGFR exon 20 insertion NSCLC
🚨 Today (press release):
1L Firmonertinib vs. chemotherapy
(FURVENT)
❌ Fails PFS primary end-point
⚠️ OS ‘trend’
Previously (ASCO 2026):
1L Sunvozertinib vs. chemotherapy
(WUKONG-28)
✅ Met PFS primary end-point (HR 0.65)
❓OS (immature)
Recently (WCLC 2026):
1L Zipalertinib plus chemotherapy vs. chemotherapy
(REZILIENT-3)
✅ Met PFS primary end-point (HR 0.50)
❓ OS (immature)
What does this mean for TKIs?
🤔 Firmonertinib = weakest agent
🤔 TKI+chemo = longer PFS than TKI alone
🤔 TKI +chemo vs. TKI alone debate will hinge on mature OS data & toxicity
[Quoting @StephenVLiu: Phase III FURVENT trial of 1L firmonertinib monotherapy vs pemetrexed-based chemo does not meet primary endpoint of PFS in pts with EGFR exon 20 insertion mutant NSCLC. Press release notes OS trend and clinical benefit by RR and PFSinv. Await full data.
https://t.co/1U3C2vVQHp]
🔖 3 ❤️ 4 🔁 0 👁 790
Petros Grivas @PGrivasMDPhD
RT @DrRishabhOnco: S1914: Adding immunotherapy to SBRT did NOT improve outcomes in early-stage NSCLC 🚫
Phase III SWOG/NRG S1914
High-risk, early-stage, medically inoperable NSCLC
402 eligible patients
• Atezolizumab + SBRT: 201
• SBRT alone: 201
• Atezolizumab 1200 mg q3w, up to 8 cycles
• SBRT started with cycle 3
📊 Updated efficacy
2-year PFS
• Atezo + SBRT: 66%
• SBRT: 67%
• HR 0.93 (95% CI 0.66–1.31)
2-year OS
• Atezo + SBRT: 82%
• SBRT: 82%
• HR 1.04 (95% CI 0.69–1.58)
⚠️ More toxicity
Grade ≥3 treatment-related AEs:
• Atezo + SBRT: 12%
• SBRT: 3%
Two grade 5 respiratory events occurred with atezolizumab + SBRT.
The trial closed early for futility.
🔑 Take-home:
For unselected patients with early-stage inoperable NSCLC, adding peri-SBRT atezolizumab increased toxicity without improving PFS or OS.
SBRT alone remains the standard of care.
@SWOG @NRGonc @TheLancetOncol @oncoalert
#LCSM #NSCLC #RadiationOncology #Immunotherapy
🔖 16 ❤️ 57 🔁 22 👁 4,297
VJ Oncology @VJOncology
At #WCLC26, Anne Chiang (@Annechiangmd) shares primary results from the ARTEMIS-008 trial of Ris-Rez in #SCLC, which showed improvements in OS, PFS, ORR and DCR, and a more favorable safety profile than topotecan
Watch: https://t.co/vrQc9Ep2Bz
#Oncology #LungCancer #LCSM #ImmunOnc @IASLC
🔖 2 ❤️ 6 🔁 0 👁 672
Gil Morgan, MD @weoncologists
Could this trial help refine where immunotherapy belongs in early-stage #NSCLC 🫁 rather than closing the door altogether?
[Quoting @OncoAlert: Does adding immunotherapy to SBRT ☢️ actually improve outcomes in early-stage, medically inoperable NSCLC🫁 —or simply add toxicity?
https://t.co/4JQVf24q3j
Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914)
A phase 3 multicentre trial evaluated whether adding atezolizumab to stereotactic body radiation therapy (SBRT) improves📈 outcomes in medically inoperable early-stage #NSCLC #LungCancer.
➡️ Among 402 eligible patients, atezolizumab plus SBRT did not improve overall survival compared with SBRT alone, with identical estimated 2-year survival of 82%. ➡️Combination therapy also increased grade ≥3 adverse events (12% vs 3%) and included two grade 5 respiratory events, supporting SBRT alone as standard treatment.
@AparGanti, @KashaniRojano, @joyfelicianomd, @NLindqwister, @DrMaraboyina, @KHigginsMD, @JhanelleGray, @karenkellymd
Pinging our faculty
@peters_solange, @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @jillfeldman4, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @UOzkerim, @FernandoOnco, @DrMirallas, @VanitaNoronha, @NarjustFlorezMD, @MartinReck2, @realbowtiedoc, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @p_ciracimd, @AmandaNizamMD, @scocmem, @DrVilmaPBarcia, @DraMartinezLago, @nataliagandur, @GIMedOnc, @DaisukeKotani]
🔖 1 ❤️ 2 🔁 1 👁 590
🧪 Newly Recruiting Trials
3 trials (2 phase III, 1 phase I) opened this week, testing CRB-701, izalontamab brengitecan and 177Lu-DFC413
Phase 3 · Corbus Pharmaceuticals Inc. · CRB-701 · Alabama, Arizona, California, Colorado, Connecticut, Delaware +18 more · CT.gov ↗
Phase 3 · Bristol-Myers Squibb · izalontamab brengitecan · California, Colorado, Florida, Illinois, Maryland, Minnesota +16 more · CT.gov ↗
Phase 1 · Novartis Pharmaceuticals · 177Lu-DFC413 · New Jersey · CT.gov ↗
Open all 3 on the trials page →
Agent descriptions from the NCI Thesaurus.
Prepared by Rafael Santana-Davila, M.D. Questions or feedback? Just reply to this email.
Disclaimer: This digest is AI-generated. Content may contain errors -- always verify with original sources.
Know a colleague who would find this useful? Just forward them this email.
☕ Not funded by anyone — no sponsors, no pharma. Buy me a coffee if it's useful.